- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04851275
Increasing Decision Quality for Men With Lower Urinary Tract Symptoms
Increasing Decision Quality in Older Men in Selecting Treatment Options for Lower Urinary Tract Symptoms (LUTS): A Pilot Randomized Controlled Trial
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Lower urinary tract symptoms (LUTS), often related to prostatomegaly, is common but seldom sought medical attention amongst older men. Visual-aid and shared decision-making (SDM) are potential solutions to address LUTS. The study aimed to determine the effect of a novel pictorial Visual Analogue Uroflowmetry Score (VAUS) and primary care physicians (PCP) SDM training on the decisional quality amongst men selecting their treatment options for LUTS.
This study recruited 60 multi-ethnic Asian men aged ≥50 years with moderate-to-severe LUTS (International Prostate Symptoms Score≥8 and/or QOL≥3) in a Singapore public primary care clinic. Men used the VAUS to report their symptoms. 60 men were randomly assigned to PCPs trained in SDM in the intervention group (n=30) and the other 30 to the control group (PCPs without SDM-training). Patient-physician dyad decision quality was measured using the validated SDMQ-9 (patient) and SDMQ-Doc (physician) questionnaires.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Singapore, Singapur, 150167
- Haidee Ngu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- men aged 50 years old and older attending the polyclinic for routine follow up of a chronic disease (non-communicable disease)
- have moderate-to-severe LUTS and/or poor quality of life (QOL) as assessed by the validated International Prostate Symptom Score (IPSS) of eight or more and/or its individual QOL score of three or more
- men of any local Asian ethnicity and were willing to provide written consent
- can communicate with their allocated PCP in either of the three main local languages; English, Mandarin or Malay.
Exclusion Criteria:
- have indwelling catheters
- urinary incontinence requiring diapers
- anuria due to any renal pathology
- gross hematuria
- acute urinary retention
- symptoms consistent with an acute urinary tract infection
- existing treatment of LUTS or other prostate pathology
- visual or hearing impairment which render men incapable of understanding the study procedure and providing informed consent
- men unwilling to discuss their LUTS treatment options with their PCP
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Shared decision making for men with lower urinary tract symptoms
Participants used the Visual Analogue Uroflowmetry Score so report their symptoms and were attended by Primary Care Physicians trained in shared decision making
|
Physicians in this group were trained in shared decision making
|
|
Comparador activo: No shared decision making for men with lower urinary tract symptoms
Participants did not use the Visual Analogue Uroflowmetry Score to report their symptoms and received usual care by Primary Care Physicians not trained in shared decision making
|
Physicians did not receive training in shared decision making
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Quality of the decision on the management of lower urinary tract symptoms from the patients' perspective
Periodo de tiempo: Through study completion, an average of 6 months
|
The Shared Decision Making-9 (SDMQ9) Questionnaire measures decision quality from the perspective of the patient.
Nine individual items in the questionnaire is scored from 0 to 5 on a six-point Likert scale ranging from 0 ("completely disagree") to 5 ("completely agree").
Standard scoring for the full scale is the total score, with values from 0 to 45. Higher scores indicate higher quality decisions.
|
Through study completion, an average of 6 months
|
|
Quality of the decision on the management of lower urinary tract symptoms from the physicians' perspective
Periodo de tiempo: Through study completion, an average of 6 months
|
The Shared Decision Making-Doctor (SDMQDoc) Questionnaire measures decision quality from the perspective of the physician.
Nine individual items in the questionnaire is scored from 0 to 5 on a six-point Likert scale ranging from 0 ("completely disagree") to 5 ("completely agree").
Standard scoring for the full scale is the total score, with values from 0 to 45. Higher scores indicate higher quality decisions.
|
Through study completion, an average of 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Tan Ngiap Chuan, MBBS, Singhealth polyclinic
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2018/3106
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .